PMC:7029759 / 35729-36864
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 951 | 571-575 | Gene | denotes | ACE2 | Gene:59272 |
| 952 | 738-742 | Gene | denotes | ACE2 | Gene:59272 |
| 953 | 193-194 | Gene | denotes | S | Gene:43740568 |
| 954 | 75-84 | Species | denotes | 2019-nCoV | Tax:2697049 |
| 955 | 543-552 | Species | denotes | 2019-nCoV | Tax:2697049 |
| 956 | 685-694 | Species | denotes | 2019-nCoV | Tax:2697049 |
| 957 | 842-864 | Species | denotes | human coronavirus NL63 | Tax:277944 |
| 958 | 1084-1092 | Species | denotes | patients | Tax:9606 |
| 959 | 647-656 | Disease | denotes | infection | MESH:D007239 |
| 960 | 830-834 | Disease | denotes | SARS | MESH:D045169 |
| 961 | 1111-1119 | Disease | denotes | infected | MESH:D007239 |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T678 | 75-84 | SP_7 | denotes | 2019-nCoV |
| T677 | 161-171 | GO:0042571 | denotes | antibodies |
| T676 | 193-202 | PG_1 | denotes | S protein |
| T675 | 343-357 | BV_15 | denotes | immunogenicity |
| T674 | 359-366 | CHEBI:59132;CHEBI:59132 | denotes | antigen |
| T673 | 381-389 | CHEBI:60809;CHEBI:60809 | denotes | adjuvant |
| T672 | 411-419 | GO:0042571 | denotes | antibody |
| T671 | 437-442 | NCBITaxon:10239 | denotes | virus |
| T670 | 543-552 | SP_7 | denotes | 2019-nCoV |
| T669 | 571-575 | G_3;PG_10;PR:000003622 | denotes | ACE2 |
| T668 | 685-694 | SP_7 | denotes | 2019-nCoV |
| T667 | 738-742 | G_3;PG_10;PR:000003622 | denotes | ACE2 |
| T666 | 830-834 | SP_10 | denotes | SARS |
| T665 | 842-847 | SP_6;NCBITaxon:9606 | denotes | human |
| T664 | 848-859 | NCBITaxon:11118 | denotes | coronavirus |
| T663 | 971-977 | SO:0000440 | denotes | vector |
| T662 | 991-996 | NCBITaxon:10239 | denotes | viral |
| T661 | 997-1003 | SO:0000440 | denotes | vector |
| T660 | 1129-1134 | NCBITaxon:10239 | denotes | virus |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T224 | 195-202 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
| T225 | 229-236 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
| T226 | 411-419 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
| T227 | 1011-1015 | Body_part | denotes | mRNA | http://purl.org/sig/ont/fma/fma67122 |
| T228 | 1023-1030 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
LitCovid_AGAC
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| p4619s14 | 730-737 | NegReg | denotes | reduced |
| p4619s15 | 738-742 | Protein | denotes | ACE2 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T123 | 647-656 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T124 | 830-834 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T372 | 6-7 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T373 | 437-442 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T374 | 576-578 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
| T375 | 842-847 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
| T376 | 1042-1043 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T377 | 1129-1134 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T156 | 195-202 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T157 | 229-236 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T158 | 359-366 | Chemical | denotes | antigen | http://purl.obolibrary.org/obo/CHEBI_59132 |
| T159 | 381-389 | Chemical | denotes | adjuvant | http://purl.obolibrary.org/obo/CHEBI_60809 |
| T160 | 1023-1030 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T22 | 359-379 | http://purl.obolibrary.org/obo/GO_0019882 | denotes | antigen presentation |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T222 | 0-237 | Sentence | denotes | While a therapeutic strategy is being outlined here, the long-term goal of 2019-nCoV research would remain developing an effective vaccine to yield neutralizing antibodies, likely based on the S protein and specifically, the RBD protein. |
| T223 | 238-432 | Sentence | denotes | Such trials should happen as soon as possible, but may prove to be challenging to get the right level of immunogenicity, antigen presentation, adjuvant addition, and potent antibody stimulation. |
| T224 | 433-527 | Sentence | denotes | The virus could continue mutating, foiling different efforts to stimulate protective immunity. |
| T225 | 528-657 | Sentence | denotes | By comparison, 2019-nCoV cannot escape the ACE2-Fc treatment strategy, since it leverages its own cognate receptor for infection. |
| T226 | 658-868 | Sentence | denotes | As mentioned above, should 2019-nCoV attempt to escape this therapy via reduced ACE2 affinity binding, it would likely become less pathogenic, similar to the comparison of SARS versus human coronavirus NL63 65. |
| T227 | 869-1135 | Sentence | denotes | Lastly, scaling the dose of any effective vaccine would also prove to be challenging depending on the vector format (e.g. viral vector versus mRNA versus protein), and even a fully protective vaccine would not help patients who are currently infected with the virus. |